Autopsy report · NCT02386111

A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma

“Portfolio re-prioritization”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 2 years 6 months before it stopped.
• 17 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Celldex Therapeutics

Sponsor type

Industry

Conditions

Carcinoma, Renal Cell; Kidney Diseases; Kidney Neoplasms; Urogenital Neoplasms; Urologic Diseases; Urologic Neoplasms

Interventions

Combination of varlilumab and sunitinib

Participants

17

Sites

9

Countries

United States

Trials that died the same way

• Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers
  “Portfolio reprioritization” (73% match in meaning)
• Safety Study of SEA-CD40 in Cancer Patients
  “Study closed due to portfolio prioritization” (69% match in meaning)
• A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
  “termination due to portfolio prioritization” (67% match in meaning)
• Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer
  “Sponsor decision based on portfolio prioritization” (62% match in meaning)
• Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
  “Project discontinued to prioritize other key programs in portfolio” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.